WYETH-AYERST CONJUGATED ESTROGENS FIGHT TAKES ON CONGRESSIONAL FLAVOR: CAPITOL HILL LETTERS TO FDA QUESTION PENDING APPLICATIONS FOR PREMARIN GENERICS
Wyeth-Ayerst is enlisting political support in its attempt to prevent FDA from approving generic versions of its topselling conjugated estrogens product Premarin. At least eight senators and members of the House have written the agency in the past month to voice concern about the imminent approval of a generic conjugated estrogen product.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth